{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.37","value":"1.3"},{"groupId":"OG001","spread":"13.28","value":"0.1"},{"groupId":"OG002","spread":"12.67","value":"0.6"}]}],"title":"Cycle 4 - approximately Month 4 (n=113,120,125)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.22","value":"0.4"},{"groupId":"OG001","spread":"14.27","value":"-1.7"},{"groupId":"OG002","spread":"12.94","value":"1.8"}]}],"title":"Cycle 7 - approximately Month 7 (n=95,108,111)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.46","value":"-1.6"},{"groupId":"OG001","spread":"15.99","value":"0.0"},{"groupId":"OG002","spread":"12.61","value":"0.3"}]}],"title":"Cycle 10 - approximately Month 10 (n=85,89,94)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.61","value":"-3.8"},{"groupId":"OG001","spread":"14.59","value":"-1.0"},{"groupId":"OG002","spread":"12.60","value":"0.3"}]}],"title":"Cycle 13 - approximately Month 13 (n=72,72,81)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.95","value":"-2.1"},{"groupId":"OG001","spread":"14.16","value":"-2.9"},{"groupId":"OG002","spread":"12.23","value":"-0.9"}]}],"title":"Cycle 16 - approximately Month 16 (n=62,50,61)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"153"},{"groupId":"OG002","value":"154"}],"units":"Participants"}],"description":"Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale; higher score for the side effects scale = higher level of symptomatology.","dispersionType":"Standard Deviation","groups":[{"description":"Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.","id":"OG000","title":"MPR+R"},{"description":"Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.","id":"OG001","title":"MPR+p"},{"description":"Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.","id":"OG002","title":"MPp+p"}],"paramType":"MEAN","populationDescription":"Intent to treat population","reportingStatus":"POSTED","timeFrame":"Baseline (Day 0), Months 4, 7, 10, 13, 16","title":"Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) In Side Effects of Treatment Scale","type":"SECONDARY","unitOfMeasure":"units on a scale"}